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Abstract
Preeclampsia is a major pregnancy complication, characterized by severe endothelial dysfunction, hypertension and
maternal end-organ damage. Soluble endoglin is an anti-angiogenic protein released from placenta and thought to play a
central role in causing the endothelial dysfunction and maternal organ injury seen in severe preeclampsia. We recently
reported MMP-14 was the protease producing placentally-derived soluble endoglin by cleaving full-length endoglin present
on the syncytiotrophoblast surface. This find identifies a specific drug target for severe preeclampsia; interfering with MMP-
14 mediated cleavage of endoglin could decrease soluble endoglin production, ameliorating clinical disease. However,
experimental MMP-14 inhibition alone only partially repressed soluble endoglin production, implying other proteases might
have a role in producing soluble endoglin. Here we investigated whether MMP-15–phylogenetically the closest MMP
relative to MMP-14 with 66% sequence similarity–also cleaves endoglin to produce soluble endoglin. MMP-15 was localized
to the syncytiotrophoblast layer of the placenta, the same site where endoglin was localized. Interestingly, it was
significantly (p=0.03) up-regulated in placentas from severe early-onset preeclamptic pregnancies (n=8) compared to
gestationally matched preterm controls (n=8). However, siRNA knockdown of MMP-15 yielded no significant decrease of
soluble endoglin production from either HUVECs or syncytialised BeWo cells in vitro. Importantly, concurrent siRNA
knockdown of both MMP-14 and MMP-15 in HUVECS did not yield further decrease in soluble endoglin production
compared to MMP-14 siRNA alone. We conclude MMP-15 is up-regulated in preeclampsia, but does not cleave endoglin to
produce soluble endoglin.
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Introduction
Preeclampsia affects 3–5% of pregnancies and is a leading cause
of maternal and perinatal mortality and morbidity. [1,2] Delivery
of the baby and placenta is the only current cure; however if the
pregnancy is considerably preterm, this inflicts severe prematurity
on the baby.
A significant advance in the understanding of its pathogenesis
was made with the characterization of two anti-angiogenic
proteins - soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble
endoglin (sEng) - as the likely factors released from preeclamptic
placentas causing endothelial dysfunction and maternal organ
injury. Both are significantly up-regulated in the sera of women
with preeclampsia with levels correlating with clinical disease
severity. Adenoviral administration of sFlt-1 to rats induces
hypertension and proteinuria, hallmarks of preeclampsia. Impor-
tantly, co-administration of both sFlt-1 and sEng to rats
recapitulates the full spectrum of end-organ injury seen in severe
preeclampsia (severe proteinuria, low platelets, deranged liver
function tests and cerebral oedema). [3,4,5].
The characterisation of these two anti-angiogenic factors in
preeclampsia is significant as they represent targets to develop
therapeutics. A drug that either decreases the production or
biological activity of either factor could possibly quench the
disease. If developed, such a drug would be an important advance
in the management of this disease.
Full-length membrane bound endoglin is a co-receptor for
transforming growth factor-b (TGF-b), and is highly expressed on
both endothelial cells and the syncytiotrophoblast. [6] MMP-14,
also known as MT1-MMP is one of six membrane-type MMPs,
and has been widely studied for its role in cancer progression and
metastasis. [7,8,9,10] Through over-expression systems in COS-7
cells, Hawinkels et al showed MMP-14 was the cleavage protease
of membrane bound endoglin, producing soluble endoglin that is
then released. [11] Through mutagenesis experiments, they
mapped the cleavage point on membrane bound endoglin to a
specific glycine-leucine point near the transmembrane domain
region.
We subsequently reported MMP-14 was highly expressed in
placenta, co-localised with endoglin, and cleaves endoglin to
produce soluble endoglin in placental cells [12]. Our data strongly
suggests membrane bound MMP-14 was responsible for produc-
ing soluble endoglin in preeclampsia.
However, we noted inhibition of MMP-14 only partially
repressed soluble endoglin production (,50%), implying other
protease(s) might also have a role in soluble endoglin production.
We have therefore sought to characterise these other proteases and
identified MMP-15 as a strong candidate for the following reasons:
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MMPs with 66% homology at the catalytic domains [13], 2)
in silico analysis of MMP15 suggests it is expressed .30 fold
expression in placenta relative to average expression in other
tissues [14], 3) it has an interchangeable role with MMP-14 in
facilitating placental development in mice, implying shared roles in
placental biology [15]. Therefore, we examined the expression of
MMP-15 in preeclamptic placentas, localized its expression, and




Women presenting to two tertiary women’s hospitals in
Melbourne, Australia, between 2008–2009 gave informed written
consent for placental tissue collection. Placenta was obtained from
preterm pregnancies not complicated by preeclampsia (n=8) and
those complicated by severe early-onset preeclampsia (n=8).
Severe preeclamptics were diagnosed in accordance with ACOG
guidelines and included the presence of hypertension .160/110
on two occasions greater than 6 hours apart, proteinuria .5g /
day, oliguria ,500 ml/day, visual disturbance, pulmonary oede-
ma, right upper quadrant pain, abnormal liver function, throm-
bocytopenia or fetal growth restriction [16]. In addition, all
samples were obtained from cases of early-onset preterm pre-
eclampsia, defined as requiring delivery ,34 weeks gestation. Pre-
term control placentas were selected from women presenting with
pre-term rupture of membranes or spontaneous preterm labor
without evidence of infection (histopathological examination of the
placentas), hypertensive disease or maternal co-morbidities.
Patient characteristics are outlined in table 1.
Placental tissue was obtained immediately following delivery.
Placental tissue (excluding fetal membranes) was removed and
washed briefly in sterile phosphate-buffered saline (PBS). Samples
for protein extraction were frozen within 15 minutes of delivery
and stored at 280uC. A portion of each placenta was also fixed in
10% buffered formalin for histology.
Human Ethics approval was obtained for this study from both
the Southern Health Human Research Ethics Committee and the
Mercy Health Human Research Ethics Committee.
Western Blot Analysis and ELISAs
20 mg of placental lysates were separated on 10% polyacryl-
amide gels with wet transfer to PVDF membranes (Millipore,
Billerica, MA). Membranes were blocked prior to blotting
overnight with an antibody targeting MMP-15 (1:1000, Millipore,
Billerica, MA) or GAPDH (1:5000, Cell Signalling Technology,
Danvers, MA). Membranes were then visualized using an
enhanced chemiluminescence detection system (Santa Cruz
Biotechnology) and ChemiDoc XRS (BioRad, Hercules, CA).
GAPDH was used as a loading control. Relative densitometry was
determined using Image Lab (BioRad).
Soluble endoglin levels were measured in conditioned culture
media using the human endoglin ELISA (R&D systems according
to manufacturer’s instructions. Optical density was determined
using a BioRad X-Mark microplate spectrophotometer (BioRad)
and endoglin levels determined using BioRad Microplate manager
6 software.
Immunohistochemistry
Endoglin and MMP-15 immunhistochemistry was conducted
on placental tissue collected from either pre-eclamptic or pre-term
control pregnancies. Paraffin sections (5 mm) of formalin-fixed
tissues were dewaxed in Xylene and rehydrated through
descending grades of ethanol. Sections were then heated for
20 min on defrost in a 700-W microwave, followed by cooling to
room temperature (RT) for 30 mins. They were washed for
10 min in Phosphate-buffered saline pH 7.6 (PBS), and immersed
in 3% H2O2 in methanol for 10 min at RT. Sections were then
washed with PBS, before immersion into Dako blocking buffer
(DAKO) for 10 mins and incubated for 1 h at RT with mouse anti
human MMP-15 (R&D systems, MN, USA) at 25 mg/ml in
1%BSA/PBS. For Isotype controls, primary antibody was
substituted with mouse IgG. The SuperPicTure kit (Invitrogen,
Carlsbad, CA) was the applied according to manufacturer’s
instructions to reveal the MMP-15 staining. Sections were lightly
counterstained with Harris hematoxylin (Accustain; Sigma Diag-
nostics, Castle Hill, NSW, Australia), dehydrated, and mounted
using DPX mounting medium (BDH Laboratory Supplies, Poole,
England). For co-localisation studies, serial sections (2 mm) were
stained in the same manner as described above.
siRNA Knockdown of MMP-14 and MMP-15 in vitro
For siRNA experiments, both human umbilical vein endothelial
cells (HUVEC – cell line) and syncytialised BeWo cells were used.
HUVECs were transfected with either 10 nM MMP-14 siRNA
(Qiagen), MMP-15 siRNA (Qiagen), combined MMP-14+ MMP-
15 siRNA, negative control siRNA (Qiagen) or transfection
Table 1. Clinical Characteristics of the preeclamptic cohort.
Preterm Control (n=8) Preeclampsia (n=8)
Maternal Age Mean years (6SEM) 31.0 (1.2) 32.6 (1.6)
Gestation at Delivery Mean weeks (6SEM) 30.9 (0.9) 32.2 (1.3)
Ethinicity–No. (%) Caucasian Asian 7 (87.5) 1(12.5) 5 (62.5) 3 (37.5)
BMI (kg/m
2) Mean (6SEM) 30.9 (1.7) 26.4 (1.7)
Primiparous No. (%) 2 (25) 5 (62.5)
SBP at Delivery Mean mmHg (6SEM) 121.0 (3.3) 172.1 (5.8)**
DBP at Delivery Mean mmHg (6SEM) 73.4 (3.1) 110.7 (4.7)**
Birthweight Mean grams (6SEM) 1622 (176.4) 1551 (268.3)
Shown are clinical details of the two cohorts from whom we obtained placentas for our analyses. The preeclamptic cohort all had severe preeclampsia necessitating
delivery preterm. Preterm controls where those who were delivered early for other indications but did not have preeclampsia. **p,0.001. SEM= standard error of the
mean, SBP= systolic blood pressure, DBP= diastolic blood pressure, BMI= body mass index and GA= gestational age.
doi:10.1371/journal.pone.0039864.t001
MMP-15 Does Not Cleave Endoglin in Preeclampsia
PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e39864reagent alone (Lipofectamine RNAiMAX, Invitrogen). Treat-
ments were applied for 48 h before media was changed and
collected 24 h later for endoglin ELISA and cell lysates were
collected for mRNA extraction.
BeWo cells were first syncytialised with 20 uM forskolin and left
for 48 h. Thereafter they were treated with 40 nM siRNAs as
described for HUVECs above. Treatments were applied for 48 h
before media was collected for endoglin ELISA and cell lysates
were collected for mRNA extraction. All experiments were
repeated a minimum of 3 times with at least 4 replicates per
treatment.
RT-PCR
To assess the efficiency of siRNA knockdown, RNA was
extracted from HUVEC or BeWo lysates using RNeasy mini kit
(Qiagen, Valencia, CA). 0.2 mg of RNA was then converted to
cDNA using SuperScript III (Invitrogen) and random hexamers
(Invitrogen) as per manufacturers guidelines. Taqman gene
Figure 1. MMP-15 is localised to the syncytiotrophoblast and up-regulated in preeclamptic placenta. Representative immunohisto-
chemistry for endoglin (A, B) and MMP-15 (D, E), shows both proteins localize to the syncytiotrophoblast in pre-eclamptic (A, D) and pre-term
control (B, E) placentas. Immunohistochemistry on serial sections (2 mm) of placenta revealed co-localisation of endoglin (G) and MMP-15 (H) to the
syncytiotrophoblast. No staining was observed in isotype controls (C, F). Densitometric analysis of western blots for MMP-15 (I, J) revealed a
significant increase in preeclamptic placentas (n=8) compared to pre-term controls (n=8). *p#0.05.
doi:10.1371/journal.pone.0039864.g001
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(Applied Biosystems, Carlsbad, CA). RT-PCR was performed on
the CFX 384 (Biorad, Hercules, CA) using FAM-labelled Taqman
universal PCR mastermix (Applied Biosystems) with the following
run conditions: 50uC for 2 minutes; 95uC for 10 mins; 95uC for 15
seconds and 60uC for 1 minute (40 cycles). PCR product was
confirmed by gel electrophoresis. Relative quantification was
determined using the comparative CT method.
Statistical Analysis
Continuous variables were compared using either an unpaired
t-test to assess parametric data or a Mann Whitney U for non-
parametric data. Categorical values were compared using the Chi-
squared test. P#0.05 was considered significant. All statistical
analysis was undertaken using GraphPad Prism (GraphPad
Software, La Jolla, CA).
Results
MMP-15 is Localized to the Syncytiotrophoblast and Up-
regulated in Preeclampsia
We first examined expression of MMP-15 in severe, preterm
pre-eclamptic placentas and preterm controls. Given soluble
endoglin has been implicated in severe preeclampsia, we only
examined placentas obtained from cases of very severe disease.
Thus, in our entire preeclamptic cohort, iatrogenic preterm
delivery was required (,34 weeks gestation) for maternal or fetal
indications. The preterm controls were cases of either spontaneous
onset of labour or premature rupture of membranes where there
was no evidence of maternal infection or hypertensive disease. All
samples were collected by caesarean section.
We first assessed endoglin by immunohistochemistry and
confirmed it was localized to the syncytiotrophoblast in both
pre-eclamptic and pre-term placenta (Figure 1 A, B), consistent
with our previous report [12]. We then stained MMP-15 by
immunohistochemistry and also found that it localized to the
syncytiotrophoblast in both pre-eclamptic and pre-term placenta
(Figure 1 D, E). Importantly, immunohistochemistry for MMP-15
and endoglin on serially sectioned placenta indicated co-localisa-
tion of the two proteins within the syncytiotrophoblast layer
(Figure 1G,H).
Next, we measured expression of MMP-15 in placenta from
women with severe early-onset preeclampsia (n=8) and gesta-
tionally matched preterm controls (n=8). Western analysis
showed MMP-15 was increased in preeclamptic placentas
compared to preterm controls (Figure 1I,J; p=0.03).
MMP-15 Knockdown does not Reduce soluble Endoglin
Production by HUVECs or Syncytialised BeWos
We next investigated whether inhibiting MMP-15 using siRNAs
would decrease soluble endoglin production in vitro using
syncytialised BeWos. This cell line best models the syncytiotro-
phoblast, and we have previously screened a number of placental
cell lines and found syncytialised Bewos to be the highest producer
of soluble endoglin [12].
Of all tissues in the body, endoglin is most highly expressed in
placenta and endothelial cells [14]. Therefore, we also examined
the effects of MMP-15 inhibition in HUVECs where we also
knocked down MMP-14.
We first confirmed siMMP-14, 15, alone, or 14 and 15 in
combination resulted in .85% knockdown compared to negative
siRNA in HUVEC cells. In syncytialised BeWos MMP-14 siRNA
yielded a mean mRNA knockdown of 35.563.9%, whilst MMP-
15 siRNA yielded a 77.464.2% knockdown compared to negative
siRNA. Similar knockdown efficiency was observed when both
siRNAs were added in combination.
In HUVEC cells, MMP-14 siRNA significantly decreased sEng
by 6165.5% (p,0.0001 compared to non-targeting siRNA
controls), MMP-14 and MMP-15 siRNA in combination induced
a4 2 64.9% decrease in sEng (p,0.0001), whilst MMP-15 siRNA
alone caused no significant change in sEng compared to negative
siRNA (Figure 2A). In syncytialised BeWo cells, MMP-14 siRNA
significantly (p,0.05) decreased sEng by 18.561.0% when
transfected alone, whilst combination MMP14+ MMP15 siRNA
significantly reduced (p,0.05) sEng production by 22.162.6%.
No significant change in sEng levels was detected following MMP-
15 knockdown alone (Figure 2B). Together these data indicate that
MMP-15 does not cleave endoglin to produce soluble endoglin in
Figure 2. MMP-15 inhibtion does not decrease soluble
endoglin production in vitro. Treatment of HUVEC cells (A) and
syncytialised BeWo cells (B) with MMP-14 siRNA alone or in
combination with MMP-15 siRNA induced a significant decline in sEng
production compared to scrambled siRNA, whilst MMP-15 siRNA alone
had no effect. Data shown as mean6SEM, n=3 experiments, *p#0.05.
doi:10.1371/journal.pone.0039864.g002
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exhibit the highest expression of endoglin of all tissues in the body.
Discussion
We recently demonstrated that MMP-14 is the cleavage
protease responsible for soluble endoglin release from placenta.
However, in those functional studies where we used placental cells
and both in vitro and in vivo models, we were only able to partially
decrease sEng release. This suggested other unidentified proteases
might also have a role in producing this anti-angiogenic factor.
We therefore undertook this current study to examine whether
MMP-15 might be such a protease given its homology to MMP-14
[13], its high placental expression [17] and the fact that both
MMP-14 and 15 have recently been shown to have interchange-
able roles for placental labyrinth formation and development in
mice [15]. In that study where knock-out mice were used, MMP-
15 was able to entirely compensate for the absence of MMP-14
with severe phenotypic effects only observed when both were
deleted.
The MMP family consists of 24 zinc-dependent endopeptidases.
MMP-15, is one of six membrane-type MMPs, which are further
classified based upon their cell surface association: MT1, 2, 3 and
5 (also known as MMP-14, 15, 16 and 24) have a transmembrane
domain, whilst MT4 and 6 (also known as MMP-17 and MMP-25)
are glycophosphatidylinositol anchored. [7,8,9,10].
MMP-15 is expressed in a variety of human tissues including
leukocytes, endothelial cells, hepatocytes and placenta
[17,18,19,20]. It cleaves gelatin and can degrade a wide range
of extracellular matrix molecules including fibronectin and
aggrecan [21]. Like MMP-14, MMP-15 has been most widely
studied for its role in cancer progression and metastasis, primarily
through its capacity to cleave and activate MMP-2 [22,23,24]. In
this study we have shown MMP-15 is localized to the syncytio-
trophoblast and is up-regulated in preeclamptic placentas. We can
only speculate on the possible role, if any, that MMP-15 may play
in the pathogenesis of preeclampsia. It may be possible that
aberrant up-regulation of MMP-15 in preeclampsia may be
responsible for the activation of MMP-2, which has also been
reported to be upregulated in pre-eclampsia and may contribute to
endothelial dysfunction [25].
However, our functional studies suggest MMP-15 is not
involved the production of soluble endoglin from either placental
or endothelial cells. In both BeWo and HUVEC cells MMP-15
targeted siRNA knockdown produced no significant decline in
sEng production compared to control siRNA. Concurrent
knockdown of both MMP-14 and 15 did not reduce sEng
significantly more than MMP-14 silencing alone. The fact sEng
continues to be produced both in this series of experiments and in
our previous report that focused on MMP-14 [12] suggests a
further mechanism of sEng production exists and awaits charac-
terization.
Acknowledgments
We thank the women who kindly donated their placental tissues used in
this work.
Author Contributions
Conceived and designed the experiments: TK KP ST. Performed the
experiments: TK KP LT LY. Analyzed the data: TK KP LT LY ST.
Contributed reagents/materials/analysis tools: TK KP ST. Wrote the
paper: TK KP ST.
References
1. Powe CE, Levine RJ, Karumanchi SA (2011) Preeclampsia, a disease of the
maternal endothelium: the role of antiangiogenic factors and implications for
later cardiovascular disease. Circulation 123: 2856–2869.
2. Sibai B, Dekker G, Kupferminc M (2005) Pre-eclampsia. Lancet 365: 785–799.
3. Maynard S, Min JY, Merchan J, Lim KH, Li J, et al (2003) Excess placental
soluble fms-like tyrosine kinase 1 (sFlt-1) may contribute to endothelial
dysfunction, hypertension, and proteinuria in pre-eclampsia. The Journal of
Clinical Investigation 111: 649–658.
4. Maynard SE, Karumanchi SA (2011) Angiogenic factors and preeclampsia.
Semin Nephrol 31: 33–46.
5. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, et al. (2006) Soluble
endoglin contributes to the pathogenesis of preeclampsia. Nat Med 12: 642–649.
6. Gougos A, St Jacques S, Greaves A, O’Connell PJ, d’Apice AJ, et al. (1992)
Identification of distinct epitopes of endoglin, an RGD-containing glycoprotein
of endothelial cells, leukemic cells, and syncytiotrophoblasts. Int Immunol 4: 83–
92.
7. Devy L, Huang L, Naa L, Yanamandra N, Pieters H, et al. (2009) Selective
inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and
angiogenesis. Cancer Res 69: 1517–1526.
8. Perentes JY, Kirkpatrick ND, Nagano S, Smith EY, Shaver CM, et al. (2011)
Cancer cell-associated MT1-MMP promotes blood vessel invasion and distant
metastasis in triple-negative mammary tumors. Cancer Res 71: 4527–4538.
9. Rozanov DV, Savinov AY, Williams R, Liu K, Golubkov VS, et al. (2008)
Molecular signature of MT1-MMP: transactivation of the downstream universal
gene network in cancer. Cancer Res 68: 4086–4096.
10. Sabbota AL, Kim HR, Zhe X, Fridman R, Bonfil RD, et al. (2010) Shedding of
RANKL by tumor-associated MT1-MMP activates Src-dependent prostate
cancer cell migration. Cancer Res 70: 5558–5566.
11. Hawinkels LJ, Kuiper P, Wiercinska E, Verspaget HW, Liu Z, et al. (2010)
Matrix metalloproteinase-14 (MT1-MMP)-mediated endoglin shedding inhibits
tumor angiogenesis. Cancer Res 70: 4141–4150.
12. Kaitu’u-Lino TJ, Palmer KR, Whitehead CL, Williams E, Lappas M, et al.
(2012) MMP-14 is expressed in preeclamptic placentas and mediates release of
soluble endoglin. Am J Pathol In press.
13. Takino T, Sato H, Shinagawa A, Seiki M (1995) Identification of the second
membrane-type matrix metalloproteinase (MT-MMP-2) gene from a human
placenta cDNA library. MT-MMPs form a unique membrane-type subclass in
the MMP family. J Biol Chem 270: 23013–23020.
14. BioGPS (2012) Gene Portal System. In: BioGPS.org, editor.
15. Szabova L, Son MY, Shi J, Sramko M, Yamada SS, et al. (2011) Membrane-
type MMPs are indispensable for placental labyrinth formation and develop-
ment. Blood 116: 5752–5761.
16. ACOG (2002) Diagnosis and Management of Pre-eclampsia and Eclampsia.
ACOG Practice Bulletin No. 33. Obstet Gynecol 99: 159–167.
17. Bjorn SF, Hastrup N, Larsen JF, Lund LR, Pyke C (2000) Messenger RNA for
membrane-type 2 matrix metalloproteinase, MT2-MMP, is expressed in human
placenta of first trimester. Placenta 21: 170–176.
18. Bar-Or A, Nuttall RK, Duddy M, Alter A, Kim HJ, et al. (2003) Analyses of all
matrix metalloproteinase members in leukocytes emphasize monocytes as major
inflammatory mediators in multiple sclerosis. Brain 126: 2738–2749.
19. Lafleur MA, Handsley MM, Knauper V, Murphy G, Edwards DR (2002)
Endothelial tubulogenesis within fibrin gels specifically requires the activity of
membrane-type-matrix metalloproteinases (MT-MMPs). J Cell Sci 115: 3427–
3438.
20. Theret N, Musso O, L’Helgoualc’h A, Campion JP, Clement B (1998)
Differential expression and origin of membrane-type 1 and 2 matrix
metalloproteinases (MT-MMPs) in association with MMP2 activation in injured
human livers. Am J Pathol 153: 945–954.
21. d’Ortho MP, Will H, Atkinson S, Butler G, Messent A, et al. (1997) Membrane-
type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic
capacities comparable to many matrix metalloproteinases. Eur J Biochem 250:
751–757.
22. Nakada M, Nakamura H, Ikeda E, Fujimoto N, Yamashita J, et al. (1999)
Expression and tissue localization of membrane-type 1, 2, and 3 matrix
metalloproteinases in human astrocytic tumors. Am J Pathol 154: 417–428.
23. Ohnishi Y, Tajima S, Ishibashi A (2001) Coordinate expression of membrane
type-matrix metalloproteinases-2 and 3 (MT2-MMP and MT3-MMP) and
matrix metalloproteinase-2 (MMP-2) in primary and metastatic melanoma cells.
Eur J Dermatol 11: 420–423.
24. Sato H, Okada Y, Seiki M (1997) Membrane-type matrix metalloproteinases
(MT-MMPs) in cell invasion. Thromb Haemost 78: 497–500.
25. Myers JE, Merchant SJ, Macleod M, Mires GJ, Baker PN, et al. (2005) MMP-2
levels are elevated in the plasma of women who subsequently develop
preeclampsia. Hypertens Pregnancy 24: 103–115.
MMP-15 Does Not Cleave Endoglin in Preeclampsia
PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e39864